Amol Akhade/hiranandanihospital.org
May 15, 2025, 10:38
Highlights from ESMO Breast 2025 by Amol Akhade
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:
“New ADC frontier in breast cancer: B7-H4 targeted therapies show promise!
Highlights from ESMO Breast 2025:
1. Puxitatug Samrotecan in HR+/HER2– metastatic breast cancer (no prior Topo1i ADC)
B7-H4 expressed in 45.4% of tumors
Confirmed ORR:• 40% at 1.6 mg/kg
• 29.6% at 2.4 mg/kgFavourable safety profile: low ILD and discontinuation
Emerging questions: HER2-low cross-activity? Timing/stability of B7-H4 expression?
2. Emiltatug Ledadotin in heavily pretreated B7-H4 high TNBC with prior Topo1i ADC
– Confirmed ORR: 23% (3/13); rises to 29% in those with ≤4 prior lines
– No responses in B7-H4 low tumorsPFS:
• 16 weeks (B7-H4 high)
• 6.4 weeks (B7-H4 low)Prior ADC exposure:
• 86% Sacituzumab
• 31% Trastuzumab deruxtecan
Key Takeaways
– B7-H4 is emerging as a valid biomarker
– Activity observed even post-TROP2/HER2-directed ADCs
– Differentiated toxicity + non-cross resistance = future potentialThe challenge?
Mapping the right biomarker + agent + timing combo in a crowded ADC landscape.”
More updates on ESMO Breast 2025 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 15, 2025, 10:38
May 15, 2025, 10:33
May 15, 2025, 10:23
May 15, 2025, 09:53
May 15, 2025, 09:08